Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) rose 5.5% during mid-day trading on Monday . The stock traded as high as $18.63 and last traded at $18.55. Approximately 60,256 shares changed hands during trading, a decline of 86% from the average daily volume of 425,623 shares. The stock had previously closed at $17.59.
Analyst Ratings Changes
A number of research analysts recently commented on BCAX shares. HC Wainwright started coverage on shares of Bicara Therapeutics in a report on Friday, December 6th. They issued a "buy" rating and a $42.00 price target for the company. Morgan Stanley assumed coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They issued an "overweight" rating and a $35.00 target price for the company. RODMAN&RENSHAW upgraded Bicara Therapeutics to a "strong-buy" rating in a research report on Tuesday, November 5th. TD Cowen started coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They issued a "buy" rating on the stock. Finally, Rodman & Renshaw initiated coverage on Bicara Therapeutics in a research report on Tuesday, November 5th. They set a "buy" rating and a $48.00 target price for the company. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Bicara Therapeutics presently has an average rating of "Buy" and a consensus target price of $43.00.
Read Our Latest Report on BCAX
Bicara Therapeutics Price Performance
The company's fifty day moving average price is $20.79.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($1.14). As a group, equities analysts forecast that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.
Institutional Trading of Bicara Therapeutics
Institutional investors have recently modified their holdings of the company. Cinctive Capital Management LP bought a new position in shares of Bicara Therapeutics during the 3rd quarter worth approximately $229,000. Barclays PLC acquired a new stake in shares of Bicara Therapeutics in the 3rd quarter worth $255,000. Jane Street Group LLC purchased a new position in Bicara Therapeutics during the 3rd quarter worth $309,000. Teachers Retirement System of The State of Kentucky purchased a new stake in Bicara Therapeutics in the third quarter valued at about $358,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Bicara Therapeutics in the third quarter valued at about $462,000.
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
See Also
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
